DRUG · Mapped RxNorm record
Rebif
Normalized identity: RebifView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
NCT01601119
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Other: Disease modifying therapies (DMT)
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedImpact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Relapsing Multiple Sclerosisunresolved
Interventions
RebifDRUG · verified · RxNorm: Rebif
Sponsors & collaborators
Merck KGaA, Darmstadt, Germanylead sponsor
Merck Serono Limited, UKcollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01601119 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.